Xue Zongqian, Zhu Jinbiao, Liu Juan, Wang Lingli, Ding Jijun
Department of Cardiology, Aoyang Hospital Affiliated to Jiangsu University, Zhangjiagang, China.
Front Cardiovasc Med. 2023 Jul 14;10:1210762. doi: 10.3389/fcvm.2023.1210762. eCollection 2023.
Atrial fibrillation (AF) is a common arrhythmia in clinic, and its incidence is increasing year by year. In today's increasingly prevalent society, ageing poses a huge challenge to global healthcare systems. AF not only affects patients' quality of life, but also causes thrombosis, heart failure and other complications in severe cases. Although there are some measures for the diagnosis and treatment of AF, specific serum markers and targeted therapy are still lacking. In recent years, ncRNAs have become a hot topic in cardiovascular disease research. These ncRNAs are not only involved in the occurrence and development of AF, but also in pathophysiological processes such as myocardial infarction and atherosclerosis, and are potential biomarkers of cardiovascular diseases. We believe that the understanding of the pathophysiological mechanism of AF and the study of diagnosis and treatment targets can form a more systematic diagnosis and treatment framework of AF and provide convenience for individuals with AF and the society.
心房颤动(AF)是临床上常见的心律失常,其发病率逐年上升。在当今社会日益普遍的老龄化背景下,这给全球医疗保健系统带来了巨大挑战。AF不仅影响患者的生活质量,严重时还会导致血栓形成、心力衰竭等并发症。尽管目前有一些针对AF的诊断和治疗措施,但仍缺乏特异性血清标志物和靶向治疗方法。近年来,非编码RNA(ncRNAs)已成为心血管疾病研究的热点。这些ncRNAs不仅参与AF的发生发展,还涉及心肌梗死和动脉粥样硬化等病理生理过程,是心血管疾病的潜在生物标志物。我们认为,对AF病理生理机制的理解以及诊断和治疗靶点的研究能够形成更系统的AF诊断和治疗框架,为AF患者个体及社会提供便利。